Mitsubishi UFJ Trust & Banking Corp Sells 90,858 Shares of Pfizer Inc. (NYSE:PFE)

Mitsubishi UFJ Trust & Banking Corp lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,837,372 shares of the biopharmaceutical company's stock after selling 90,858 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.05% of Pfizer worth $75,275,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after buying an additional 2,285,276 shares during the period. State Street Corp grew its holdings in Pfizer by 1.2% in the third quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock valued at $8,405,930,000 after purchasing an additional 3,405,539 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Geode Capital Management LLC grew its position in Pfizer by 1.6% during the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after acquiring an additional 1,855,419 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Bank of America restated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Finally, Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Stock Performance

NYSE PFE traded up $0.10 on Friday, hitting $25.11. The stock had a trading volume of 17,244,590 shares, compared to its average volume of 38,985,228. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company's 50-day moving average is $26.09 and its two-hundred day moving average is $26.97. The stock has a market cap of $142.38 billion, a price-to-earnings ratio of 17.81, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.